News | January 11, 2013

FFR Startup Company Gains $250,000 Investment

Company says its technology will better analyze coronary artery blockages

January 11, 2013 — Guided Interventions LLC, a startup company developing new, easier to use fractional flow reserve (FFR) a product to help cardiologists better assess the physiological impact of coronary artery blockages, has received a $250,000 investment commitment from nonprofit venture development organization JumpStart Inc.

Guided Interventions' novel FFR guide wire provides an easier, more effective and more affordable way to obtain FFR measurements during coronary catheterization procedures.

"An FFR measurement determines the best way to treat a coronary artery blockage - whether that entails no intervention, angioplasty or angioplasty plus stenting," said Guided Interventions' CEO, Matthew Pollman.

Using FFR measurements improves the precision of these diagnoses, potentially reducing unnecessary procedures and lowering medical costs while improving patient outcomes. "As these measurements increasingly become standard practice, we believe our user-friendly FFR guide wire will be adopted widely," Pollman said.

FFR guide wires currently available to cardiologists can be difficult to guide through an artery because their powered sensors require significant structural compromises to the interior core of a guide wire. Utilizing a passive sensor, Guided Interventions' novel guide wire solution is optimized for improved maneuverability and handling.

"FFR is a relatively new and somewhat under-utilized diagnostic technology," said Mike Lang, JumpStart's venture partner. "But thanks to a great product design and a strong management team with extensive experience in medical device development and commercialization, Guided Interventions is in a good position to enter and even lead the growing FFR guide wire market."

Guided Interventions plans to use the JumpStart investment to complete development and test an initial prototype in relevant animal models. The company also intends to launch and scale its operations in Northeast Ohio within calendar year 2013, especially by hiring engineers. "Northeast Ohio's resources - including Global Cardiovascular Innovation Center, the SMART Commercialization Center and North Coast Angel Fund - are first-rate," Pollman says. "Their presence makes the region an appealing place to found and grow our company, and gives us the ability to get traction in the medical device space."

For more information: www.jumpstartinc.org

Related Content

Angiography with a co-registered view of pressure drops according iFR readings in a coronary vessel. The DEFINE PCI study showed patients had improved outcomes and less recurrent chest pain at one year using iFR physiologic measurements combined with landmarks shown on angiographic imaging to better guide therapy. Image by Philips Healthcare. #TCT #TCT2020 #TCTconnect

Angiography with a co-registered view of pressure drops according iFR readings in a coronary vessel. The DEFINE PCI study showed patients had improved outcomes and less recurrent chest pain at one year using iFR physiologic measurements combined with landmarks shown on angiographic imaging to better guide therapy. Image by Philips Healthcare

Feature | FFR Technologies | October 30, 2020 | Dave Fornell, Editor
Fractional flow reserve (FFR) is considered the gold standard measure whether a coronary lesions needs a percutaneous
Example of FFR assessment of the coronary hemodynamic flow in lesions using the Philips FFR, iFR assessment system. #FFR #TCTconnect #TCT2020

FFR assessment of a coronary lesion using the Philips Healthcare Volcano FFR system.

News | FFR Technologies | October 23, 2020
October 23, 2020 – A new observational study of deferred lesions following combined fractional flow reserve (FFR) and
Fractional Flow reserve (FFR) selection on the Abbott, St. Jude FFR system console. The TARGET FFR study at #TCT2020 #TCTconnect.
News | FFR Technologies | October 23, 2020
October 23, 2020 – Results from the randomized controlled TARGET FFR trial show that while a physiology-guided percut
An example of a HeartFlow FFR-CT image showing the blood flow through what looked like a significant blockage on CT angiography alone actually was not flow limiting based on computational fluid dynamics. Use of the technology was supposed to reduce the number of diagnostic catheterizations in the FORECAST trial, but the costs of FFR-CT were not offset enough to show cost savings. #TCT2020 #TCTconnect

An example of a HeartFlow FFR-CT image showing the blood flow through what looked like a significant blockage on CT angiography alone, actually was not flow-limiting based on computational fluid dynamics. Use of the technology was supposed to reduce the number of diagnostic catheterizations in the FORECAST trial, but the costs of FFR-CT were not offset enough to show cost savings.

News | FFR Technologies | October 22, 2020 | Dave Fornell, Editor
October 22, 2020 – In the FORECAST randomized clinical trial, the use of ...
Philip's co-registration technology showing angiography overlaid with iFR in a coronary vessel segment with a system of dots that show regions where the hemodynamic pressure drops occur. This can aid in identifying culprit lesions. #TCT #TCT2020 #TCTconnect

Philip's co-registration technology showing angiography overlaid with iFR in a coronary vessel segment with a system of dots that show regions where the hemodynamic pressure drops occur. This can aid in identifying culprit lesions.

News | FFR Technologies | October 15, 2020
October 15, 2020 — The one-year results of the late-breaking...
The Philips Healthcare OmniWire is the world’s first solid core fractional flow reserve (FFR) pressure wire for coronary artery interventional procedures.

The Philips Healthcare OmniWire is the world’s first solid core fractional flow reserve (FFR) pressure wire for coronary artery interventional procedures.

News | FFR Technologies | August 18, 2020
August 18, 2020 — Philips Healthcare introduced its new OmniWire, the world’s first solid core...
The Acist Navvus II Rapid Exchange FFR MicroCatheter delivers even more flexibility and a streamlined crossing profile to assess complicated lesions.

The Acist Navvus II Rapid Exchange FFR MicroCatheter delivers even more flexibility and a streamlined crossing profile to assess complicated lesions.

News | FFR Technologies | July 09, 2020
July 9, 2020 – Acist Medical Systems Inc., a Bracco Group Company, announced the global launch of its Acist Navvus II
The Medis QFR technology allows non-invasive functional FFR assessment of coronary flow based on standard X-ray angiographic images in the cath lab without the use of a pressure wire.

The Medis QFR technology allows non-invasive functional FFR assessment of coronary flow based on standard X-ray angiographic images in the cath lab without the use of a pressure wire.

Feature | FFR Technologies | July 07, 2020 | Dave Fornell, Editor
An OCT intracoronary image showing instent restenosis. The white spots in the vessel wall casting shadows are the stent struts. OCT image data might be used in the future to assess FFR to determine the severity of lesions and determine if they need to be stented.

An OCT intracoronary image showing instent restenosis. The white spots in the vessel wall casting shadows are the stent struts. OCT image data might be used in the future to assess FFR to determine the severity of lesions and determine if they need to be stented.

News | FFR Technologies | May 15, 2020
May 15, 2020 – A late-breaking study aimed to evaluate whether...